Lilly completes the Centessa acquisition

Eli Lilly announced on June 24, 2026, that it has completed its acquisition of Centessa Pharmaceuticals plc, a clinical-stage company working on a new class of medicines called orexin receptor 2 agonists ^[1]. These drugs target the orexin system, a set of signals in the brain that control wakefulness, alertness, and stable sleep ^[1]. Centessa's lead program is aimed at narcolepsy, and the company says the same science could apply to other sleep-wake disorders ^[1].

The deal is now folded into Lilly Neuroscience, the division led by Carole Ho, who serves as Lilly's executive vice president and president of that unit ^[1]. In a statement, Ho said disrupted orexin signaling is "profoundly disabling" for people with narcolepsy and that Lilly intends to pursue the broader potential of orexin science "with urgency" ^[1]. Lilly's press release does not spell out a timeline, trial design, or price tag for the acquisition, and it does not disclose how many people are enrolled in Centessa's studies or how far along the lead program is in clinical testing ^[1].

This transaction sits apart from Lilly's diabetes and obesity business, which includes tirzepatide sold as Mounjaro and Zepbound. The June 24 announcement makes no mention of semaglutide, tirzepatide, orforglipron, or any GLP-1 medicine ^[1]. It is part of a pattern of Lilly expanding into neuroscience through acquisitions; the same news feed that carried this release also lists Lilly's earlier completed purchase of AtaiBeckley, a company working on treatment-resistant depression and other mental health conditions ^[1].

Why it matters for patients

For people currently taking or considering semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), this deal does not change access, price, or safety information for those medicines. Nothing in Lilly's announcement affects supply, insurance coverage, or dosing guidance for existing GLP-1 products ^[1].

The acquisition does matter for people living with narcolepsy or other sleep-wake disorders, since it signals that a major pharmaceutical company is putting resources behind an experimental drug class that works differently from existing narcolepsy treatments ^[1]. It also matters to investors and industry watchers because it shows Lilly using its scale to diversify beyond its GLP-1 franchise into neuroscience, following a similar move into mental health treatment with the AtaiBeckley deal ^[1].

It is not yet known from Lilly's statement how soon any orexin receptor 2 agonist from this portfolio might reach a regulatory filing or approval, what the treatment would cost, or how it would be positioned against other narcolepsy drugs already on the market ^[1]. The company's forward-looking language in its own release cautions that there is no guarantee the acquisition will produce a commercially successful product, and that drug development carries substantial risk and uncertainty ^[1].

What happens next

Lilly has not published a public timeline for when Centessa's orexin program might advance to late-stage trials or seek regulatory review ^[1]. Because the source material is a closing announcement rather than a clinical trial update, specific study results, enrollment numbers, and next regulatory steps are not yet available and would need to come from future Lilly disclosures ^[1].